Skip to main navigation Skip to search Skip to main content

ROMICAR: Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma

  • Fox, Sonia (Co-Investigator)
  • Fenwick, Nicola (Principal Investigator)

Project Details

Short titleROMICAR: Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
StatusFinished
Effective start/end date1/08/15 → 31/08/22

Funding

  • ONYX PHARMACEUTICALS INC
  • BLOODWISE
  • CELGENE INTERNATIONAL II SARL